Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
LAUSANNE, Switzerland--(Business Wire/Korea Newswire)--Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of ...
Free plan · Plus CA$29 or Pro CA$99/month


